Bristol-Myers Squibb Company (NYSE:BMY)
Stock Price:
$67.68
+0.7
(1.04%)
Updated
Mar 24, 2023 08:00 PM GMT+0000
| Market Cap | 142.35B |
|---|---|
| Revenue | 46.16B |
| Gross Profit | 36.02B |
| Shares Out | 2.10B |
| EPS (ttm) | 2.95 |
| PE Ratio | 22.4991 |
| Forward PE | 8.3787 |
| Dividend Rate (ttm) | 2.1655 |
| Dividend Yield | 0.0320 |
| Trading Day | Mar 24 |
|---|---|
| Last Price | $67.68 |
| Previous Close | $66.98 |
| Change ($) | 0.7 |
| Change (%) | 1.04% |
| Day's Open | 67.2 |
| Day's Range | 66.69 - 67.775 |
| Day's Volume | 6.28M |
| 52 Week Range | 64.94 - 80.8 |
About Bristol-Myers Squibb Company
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
News
Quick info
Country
United States
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Employees
34,300
CEO
Giovanni Caforio
Address
430 E 29th St Fl 14
New York
New York
10016-8367
New York
New York
10016-8367
Phone
12125464000
Website
www.bms.com
Ticker Symbol
BMY
Exchange
New York Stock Exchange
Reporting Currency
USD
Bristol-Myers Squibb Company income statements (2022) (USD)
| July 2022 | July 2022 | April 2022 | February 2022 | |
|---|---|---|---|---|
| Total Revenue | 11.89B | 11.89B | 11.65B | 11.99B |
| Cost of Revenue | 2.72B | 2.72B | 2.47B | 2.36B |
| Gross Profit | 9.17B | 9.17B | 9.18B | 9.63B |
| Research & Development | 2.32B | 2.32B | 2.26B | 2.61B |
| Selling General & Admin | 1.79B | 1.79B | 1.83B | 2.35B |
| Operating Expense | 9.25B | 9.25B | 8.98B | 9.73B |
| Operating Income | 2.64B | 2.64B | 2.67B | 2.25B |
| Other Income Expense Net | 0 | 0 | 0 | 0 |
| EBIT | 2.33B | 2.33B | 2.03B | 1.04B |
| Interest Income | 313M | 313M | 326M | 323M |
| Pretax Income | 1.96B | 1.96B | 1.69B | 1.86B |
| Income Tax | 529M | 529M | 404M | -514M |
| Minority Interest | 8M | 8M | 5M | 0 |
| Net Income | 1.42B | 1.42B | 1.28B | 2.37B |
| Net Income Basic | 1.42B | 1.42B | 1.28B | 2.37B |
Bristol-Myers Squibb Company income statements (2021) (USD)
| October 2021 | October 2021 | July 2021 | April 2021 | February 2021 | |
|---|---|---|---|---|---|
| Total Revenue | 11.62B | 11.62B | 11.70B | 11.07B | 11.07B |
| Cost of Revenue | 2.29B | 2.29B | 2.45B | 2.84B | 2.91B |
| Gross Profit | 9.33B | 9.33B | 9.25B | 8.23B | 8.16B |
| Research & Development | 3.25B | 3.25B | 3.27B | 2.23B | 3.75B |
| Selling General & Admin | 1.79B | 1.79B | 1.88B | 1.67B | 2.72B |
| Operating Expense | 9.88B | 9.88B | 10.15B | 9.25B | 11.89B |
| Operating Income | 1.75B | 1.75B | 1.55B | 1.83B | -820M |
| Other Income Expense Net | 0 | 0 | 0 | 0 | 0 |
| EBIT | 2.21B | 2.21B | 1.70B | 2.43B | -1.64B |
| Interest Income | 328M | 328M | 330M | 353M | 355M |
| Pretax Income | 2.16B | 2.16B | 1.55B | 2.53B | -10.45B |
| Income Tax | 605M | 605M | 492M | 501M | -424M |
| Minority Interest | 6M | 6M | 6M | 8M | 0 |
| Net Income | 1.55B | 1.55B | 1.06B | 2.02B | -10.03B |
| Net Income Basic | 1.55B | 1.55B | 1.06B | 2.02B | -10.03B |
Bristol-Myers Squibb Company income statements (2020) (USD)
| August 2020 | June 2020 | March 2020 | |
|---|---|---|---|
| Total Revenue | 10.13B | 10.13B | 10.78B |
| Cost of Revenue | 2.70B | 5.08B | 5.93B |
| Gross Profit | 7.43B | 5.05B | 4.85B |
| Research & Development | 2.52B | 2.48B | 2.32B |
| Selling General & Admin | 1.63B | 1.63B | 1.61B |
| Operating Expense | 9.24B | 9.19B | 9.85B |
| Operating Income | 891M | 0.94B | 0.93B |
| Other Income Expense Net | 361M | 688M | -1.23B |
| EBIT | 2.07B | 0.94B | 0.93B |
| Interest Income | 357M | 357M | 362M |
| Pretax Income | 1.63B | 1.63B | -304M |
| Income Tax | 1.71B | 1.71B | 462M |
| Minority Interest | 5M | 5M | 9M |
| Net Income | -85M | -85M | -775M |
| Net Income Basic | -85M | -85M | -775M |
Bristol-Myers Squibb Company income statements (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Total Revenue | 7.95B | 6.01B | 6.27B | 5.92B |
| Cost of Revenue | 3.53B | 1.79B | 1.87B | 1.83B |
| Gross Profit | 4.42B | 4.22B | 4.40B | 4.09B |
| Research & Development | 1.99B | 1.36B | 1.31B | 1.30B |
| Selling General & Admin | 1.73B | 1.06B | 1.08B | 1.01B |
| Operating Expense | 7.24B | 4.21B | 4.26B | 4.14B |
| Operating Income | 701M | 1.80B | 2.02B | 1.78B |
| Other Income Expense Net | -830M | -453M | -242M | 196M |
| EBIT | 701M | 1.80B | 2.02B | 1.78B |
| Interest Income | 279M | 209M | 123M | 45M |
| Pretax Income | -129M | 1.35B | 1.78B | 1.98B |
| Income Tax | 0.93B | -17M | 337M | 264M |
| Minority Interest | -4M | 13M | 7M | 5M |
| Net Income | -1.06B | 1.35B | 1.43B | 1.71B |
| Net Income Basic | -1.06B | 1.35B | 1.43B | 1.71B |
Bristol-Myers Squibb Company income statements (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Total Revenue | 5.97B | 5.69B | 5.70B | 5.19B |
| Cost of Revenue | 1.69B | 1.65B | 1.60B | 1.59B |
| Gross Profit | 4.29B | 4.04B | 4.11B | 3.60B |
| Research & Development | 1.36B | 1.26B | 2.42B | 1.23B |
| Selling General & Admin | 1.34B | 1.10B | 1.13B | 0.98B |
| Operating Expense | 4.38B | 4.01B | 5.15B | 3.80B |
| Operating Income | 1.59B | 1.68B | 559M | 1.39B |
| Other Income Expense Net | -43M | 490M | -42M | 386M |
| EBIT | 1.59B | 1.68B | 559M | 1.39B |
| Interest Income | 48M | 44M | 45M | 46M |
| Pretax Income | 1.55B | 2.17B | 517M | 1.78B |
| Income Tax | 357M | 255M | 135M | 284M |
| Minority Interest | -2M | 11M | 9M | 9M |
| Net Income | 1.19B | 1.90B | 373M | 1.49B |
| Net Income Basic | 1.19B | 1.90B | 373M | 1.49B |
Bristol-Myers Squibb Company income statements (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Total Revenue | 5.45B | 5.25B | 5.14B |
| Cost of Revenue | 1.48B | 1.56B | 1.39B |
| Gross Profit | 3.97B | 3.69B | 3.76B |
| Research & Development | 1.39B | 1.48B | 1.09B |
| Selling General & Admin | 1.30B | 1.15B | 1.17B |
| Operating Expense | 4.17B | 4.19B | 3.64B |
| Operating Income | 1.28B | 1.06B | 1.50B |
| Other Income Expense Net | -579M | 119M | -207M |
| EBIT | 1.28B | 1.06B | 1.50B |
| Interest Income | 51M | 48M | 52M |
| Pretax Income | 698M | 1.18B | 1.30B |
| Income Tax | 3.03B | 327M | 373M |
| Minority Interest | -1M | 11M | 6M |
| Net Income | -2.33B | 845M | 0.92B |
| Net Income Basic | -2.33B | 845M | 0.92B |
Bristol-Myers Squibb Company balance sheet (2022) (USD)
| July 2022 | July 2022 | April 2022 | February 2022 | |
|---|---|---|---|---|
| Current Cash | 13.27B | 13.27B | 15.20B | 17.22B |
| Receivables | 9.05B | 9.05B | 8.51B | 9.37B |
| Inventory | 2.14B | 2.14B | 2.10B | 2.10B |
| Current Assets | 30.19B | 30.19B | 30.12B | 33.26B |
| Other Current Assets | 5.57B | 5.57B | 4.16B | 4.44B |
| Short Term Investments | 5.57B | 5.57B | 4.16B | 4.44B |
| Long Term Investments | 70.17B | 70.17B | 72.91B | 76.05B |
| Property/Plant Equipment | 5.97B | 5.97B | 6.05B | 6.05B |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 37.69B | 37.69B | 40.10B | 42.53B |
| Tangible Assets (Net) | -25.54B | -25.54B | -29.02B | -27.08B |
| Other Assets | 1.86B | 1.86B | 1.48B | 1.71B |
| Total Assets | 100.36B | 100.36B | 103.03B | 109.31B |
| Accounts Payable | 2.88B | 2.88B | 2.94B | 2.95B |
| Other Current Liabilities | 13.08B | 13.08B | 12.36B | 13.97B |
| Total Current Liabilities | 20.92B | 20.92B | 22.82B | 21.87B |
| Total Liabilities | 67.76B | 67.76B | 71.45B | 73.37B |
| Long Term Debt | 37.11B | 37.11B | 37.45B | 39.61B |
| Current Long Term Debt | 4.95B | 4.95B | 7.52B | 4.95B |
| Minority Interest | 61M | 61M | 65M | 60M |
| Common Stock | 2.13B | 2.13B | 2.15B | 2.20B |
| Treasury Stock | -35.29B | -35.29B | -35.19B | -31.26B |
| Retained Earnings | 24.22B | 24.22B | 23.95B | 23.82B |
| Capital Surplus | N.A | N.A | N.A | N.A |
| Shareholder Equity | 32.60B | 32.60B | 31.58B | 35.95B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Bristol-Myers Squibb Company balance sheet (2021) (USD)
| October 2021 | October 2021 | July 2021 | April 2021 | February 2021 | |
|---|---|---|---|---|---|
| Current Cash | 15.66B | 15.66B | 14.02B | 12.93B | 16.45B |
| Receivables | 9.25B | 9.25B | 9.02B | 8.66B | 8.50B |
| Inventory | 2.16B | 2.16B | 2.14B | 1.95B | 2.07B |
| Current Assets | 31.28B | 31.28B | 29.16B | 26.90B | 30.19B |
| Other Current Assets | 4.07B | 4.07B | 3.82B | 3.22B | 3.17B |
| Short Term Investments | 4.07B | 4.07B | 3.82B | 3.22B | 3.17B |
| Long Term Investments | 79.61B | 79.61B | 81.64B | 85.53B | 88.29B |
| Property/Plant Equipment | 5.87B | 5.87B | 5.80B | 5.76B | 5.89B |
| Good Will | N.A | N.A | N.A | N.A | N.A |
| Intangible Assets | 44.93B | 44.93B | 48.07B | 50.82B | 53.24B |
| Tangible Assets (Net) | -28.24B | -28.24B | -31.79B | -33.74B | -35.97B |
| Other Assets | 1.50B | 1.50B | 1.63B | 1.74B | 1.75B |
| Total Assets | 110.89B | 110.89B | 110.80B | 112.44B | 118.48B |
| Accounts Payable | 2.70B | 2.70B | 3.61B | 2.97B | 2.71B |
| Other Current Liabilities | 13.70B | 13.70B | 12.73B | 12.58B | 14.03B |
| Total Current Liabilities | 21.46B | 21.46B | 18.99B | 17.33B | 19.08B |
| Total Liabilities | 73.68B | 73.68B | 73.99B | 74.83B | 80.66B |
| Long Term Debt | 39.68B | 39.68B | 42.50B | 44.51B | 48.34B |
| Current Long Term Debt | 5.07B | 5.07B | 2.66B | 1.78B | 2.34B |
| Minority Interest | 71M | 71M | 66M | 68M | 60M |
| Common Stock | 2.22B | 2.22B | 2.23B | 2.24B | 2.25B |
| Treasury Stock | -28.57B | -28.57B | -28.2B | -27.2B | -26.24B |
| Retained Earnings | 22.63B | 22.63B | 22.17B | 22.20B | 21.28B |
| Capital Surplus | N.A | N.A | N.A | N.A | N.A |
| Shareholder Equity | 37.21B | 37.21B | 36.81B | 37.61B | 37.82B |
| Other Liabilities | N.A | N.A | N.A | N.A | N.A |
Bristol-Myers Squibb Company balance sheet (2020) (USD)
| August 2020 | June 2020 | March 2020 | |
|---|---|---|---|
| Current Cash | 21.66B | 20.02B | 15.82B |
| Receivables | 7.86B | 6.70B | 7.20B |
| Inventory | 2.38B | 2.38B | 2.84B |
| Current Assets | 34.34B | 34.34B | 31.85B |
| Other Current Assets | 2.45B | 1.29B | 1.41B |
| Short Term Investments | 2.45B | 1.86B | 2.51B |
| Long Term Investments | 93.73B | 5.20B | 2.96B |
| Property/Plant Equipment | 5.78B | 6.48B | 6.84B |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | 59.17B | 59.17B | 61.67B |
| Tangible Assets (Net) | -30.66B | -60.07B | -63.07B |
| Other Assets | 1.67B | 1.22B | 2.91B |
| Total Assets | 128.08B | 128.08B | 129.29B |
| Accounts Payable | 2.85B | 2.85B | 3.07B |
| Other Current Liabilities | 15.75B | 13.34B | 10.17B |
| Total Current Liabilities | 23.42B | 23.42B | 19.23B |
| Total Liabilities | 78.98B | 78.92B | 79.31B |
| Long Term Debt | 41.85B | 42.56B | 43.53B |
| Current Long Term Debt | 4.82B | 4.25B | 3.26B |
| Minority Interest | 66M | 5M | 9M |
| Common Stock | 44.74B | 2.25B | 2.26B |
| Treasury Stock | -25.65B | 25.65B | 24.76B |
| Retained Earnings | 31.57B | 31.57B | 32.67B |
| Capital Surplus | N.A | 44.44B | 43.25B |
| Shareholder Equity | 49.09B | 49.09B | 49.91B |
| Other Liabilities | N.A | N.A | N.A |
Bristol-Myers Squibb Company balance sheet (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Current Cash | 12.35B | 30.49B | 28.40B | 7.34B |
| Receivables | 6.48B | 4.29B | 4.50B | 4.65B |
| Inventory | 4.29B | 1.19B | 1.31B | 1.28B |
| Current Assets | 29.35B | 40.19B | 37.72B | 17.09B |
| Other Current Assets | 1.23B | 0.95B | 1.38B | 1.29B |
| Short Term Investments | 3.05B | 2.05B | 0.95B | 1.43B |
| Long Term Investments | 4.56B | 1.19B | 1.49B | 1.36B |
| Property/Plant Equipment | 6.96B | 5.33B | 5.36B | 5.51B |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 63.97B | 1B | 1B | 1.03B |
| Tangible Assets (Net) | -61.48B | 525M | -1.06B | -1.87B |
| Other Assets | 2.11B | 1.59B | 1.63B | 1.91B |
| Total Assets | 129.94B | 57.43B | 55.16B | 34.83B |
| Accounts Payable | 2.45B | 1.89B | 2.01B | 1.98B |
| Other Current Liabilities | 10.86B | 7.42B | 6.73B | 5.92B |
| Total Current Liabilities | 18.30B | 10.49B | 9.71B | 8.84B |
| Total Liabilities | 78.25B | 39.68B | 39.01B | 19.52B |
| Long Term Debt | 44.06B | 24.89B | 24.95B | 6.16B |
| Current Long Term Debt | 2.76B | N.A | N.A | N.A |
| Minority Interest | -4M | 13M | 7M | 5M |
| Common Stock | 2.23B | 1.63B | 1.64B | 1.64B |
| Treasury Stock | 25.36B | 19.87B | 19.57B | 19.57B |
| Retained Earnings | 34.47B | 36.56B | 35.87B | 35.11B |
| Capital Surplus | 43.71B | 2.21B | 2.15B | 2.10B |
| Shareholder Equity | 51.60B | 17.65B | 16.05B | 15.22B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Bristol-Myers Squibb Company balance sheet (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Current Cash | 6.91B | 5.41B | 5B | 5.34B |
| Receivables | 5.07B | 4.82B | 4.32B | 4.37B |
| Inventory | 1.20B | 1.28B | 1.24B | 1.23B |
| Current Assets | 17.16B | 14.87B | 13.87B | 14.65B |
| Other Current Assets | 1.30B | 693M | 1B | 0.97B |
| Short Term Investments | 1.97B | 1.42B | 1.08B | 1.43B |
| Long Term Investments | 1.89B | 2.32B | 2.40B | 2.50B |
| Property/Plant Equipment | 5.03B | 5.09B | 5.08B | 5.06B |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 1.09B | 1.11B | 1.09B | 1.12B |
| Tangible Assets (Net) | -3.1B | -4.11B | -5.36B | -5.22B |
| Other Assets | 1.89B | 2.01B | 2B | 1.53B |
| Total Assets | 34.99B | 33.73B | 32.64B | 33.08B |
| Accounts Payable | 1.89B | 1.77B | 1.87B | 1.73B |
| Other Current Liabilities | 6.66B | 5.95B | 5.92B | 5.68B |
| Total Current Liabilities | 10.65B | 9.69B | 9.88B | 9.62B |
| Total Liabilities | 20.86B | 19.98B | 20.22B | 20.18B |
| Long Term Debt | 5.65B | 5.69B | 5.67B | 5.78B |
| Current Long Term Debt | 1.25B | 1.25B | 1.26B | 1.25B |
| Minority Interest | -2M | 11M | 9M | 9M |
| Common Stock | 1.62B | 1.63B | 1.63B | 1.63B |
| Treasury Stock | 19.57B | 19.58B | 19.58B | 19.43B |
| Retained Earnings | 34.07B | 33.29B | 32.04B | 32.32B |
| Capital Surplus | 2.08B | 2.03B | 1.97B | 1.92B |
| Shareholder Equity | 14.03B | 13.64B | 12.32B | 12.79B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Bristol-Myers Squibb Company balance sheet (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Current Cash | 5.42B | 4.64B | 3.47B |
| Receivables | 4.87B | 5.21B | 5.10B |
| Inventory | 1.17B | 1.25B | 1.22B |
| Current Assets | 14.85B | 15.05B | 14.32B |
| Other Current Assets | 1.27B | 1.09B | 1.14B |
| Short Term Investments | 1.39B | 2.48B | 3.04B |
| Long Term Investments | 2.55B | 2.53B | 2.58B |
| Property/Plant Equipment | 5B | 5.01B | 4.94B |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | 1.21B | 1.21B | 1.25B |
| Tangible Assets (Net) | -6.32B | -3.24B | -3.3B |
| Other Assets | 1.47B | 0.97B | 883M |
| Total Assets | 33.55B | 33.98B | 33.41B |
| Accounts Payable | 2.25B | 1.70B | 1.55B |
| Other Current Liabilities | 6.10B | 6.07B | 5.87B |
| Total Current Liabilities | 9.56B | 9.44B | 9.02B |
| Total Liabilities | 21.70B | 19.06B | 18.59B |
| Long Term Debt | 6.98B | 6.98B | 6.91B |
| Current Long Term Debt | N.A | N.A | 750M |
| Minority Interest | -1M | 11M | 6M |
| Common Stock | 1.63B | 1.64B | 1.64B |
| Treasury Stock | 19.25B | 19B | 18.78B |
| Retained Earnings | 31.16B | 34.14B | 33.93B |
| Capital Surplus | 1.90B | 1.85B | 1.79B |
| Shareholder Equity | 11.74B | 14.78B | 14.70B |
| Other Liabilities | N.A | N.A | N.A |
Bristol-Myers Squibb Company cash flow (2023) (USD)
| February 2023 | |
|---|---|
| Net Income | 2.02B |
| Depreciation | 2.52B |
| Changes in Receivables | 9.89B |
| Changes in Inventories | 2.34B |
| Cash Change | 9.25B |
| Cash Flow | 3.31B |
| Capital Expenditures | -346M |
| Investments | N.A |
| Investing Activity (other) | N.A |
| Total Investing Cash Flows | 1.21B |
| Dividends Paid | N.A |
| Net Borrowings | 24.42B |
| Other Financing Cash Flows | N.A |
| Cash Flow Financing | -3.25B |
| Exchange Rate Effect | N.A |
Bristol-Myers Squibb Company cash flow (2022) (USD)
| October 2022 | July 2022 | |
|---|---|---|
| Net Income | 1.61B | 1.42B |
| Depreciation | 2.59B | 2.58B |
| Changes in Receivables | 9.61B | 9.05B |
| Changes in Inventories | 2.07B | 2.14B |
| Cash Change | 9.03B | 13.27B |
| Cash Flow | 3.69B | 2.26B |
| Capital Expenditures | -247M | -272M |
| Investments | N.A | N.A |
| Investing Activity (other) | N.A | N.A |
| Total Investing Cash Flows | -2.08B | -289M |
| Dividends Paid | N.A | N.A |
| Net Borrowings | 24.15B | 23.22B |
| Other Financing Cash Flows | N.A | N.A |
| Cash Flow Financing | -4.54B | -3.52B |
| Exchange Rate Effect | N.A | N.A |
Bristol-Myers Squibb Company cash flow (2021) (USD)
| October 2021 | |
|---|---|
| Net Income | 1.55B |
| Depreciation | 2.73B |
| Changes in Receivables | 9.25B |
| Changes in Inventories | 2.16B |
| Cash Change | 15.66B |
| Cash Flow | 5.27B |
| Capital Expenditures | -270M |
| Investments | N.A |
| Investing Activity (other) | N.A |
| Total Investing Cash Flows | -0.98B |
| Dividends Paid | N.A |
| Net Borrowings | 25.01B |
| Other Financing Cash Flows | N.A |
| Cash Flow Financing | -1.78B |
| Exchange Rate Effect | N.A |
Bristol-Myers Squibb Company cash flow (2020) (USD)
| August 2020 | June 2020 | March 2020 | |
|---|---|---|---|
| Net Income | -85M | -85M | -775M |
| Depreciation | 5.04B | 2.56B | 2.48B |
| Changes in Receivables | -435M | 501M | -724M |
| Changes in Inventories | -452M | 642M | 1.45B |
| Cash Change | 3.34B | 4.12B | 3.43B |
| Cash Flow | 8.16B | 4.27B | 3.89B |
| Capital Expenditures | -317M | -131M | -186M |
| Investments | N.A | 0.92B | 659M |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | 1.43B | 780M | 653M |
| Dividends Paid | N.A | -1.02B | -1.02B |
| Net Borrowings | 22.57B | -48M | 26M |
| Other Financing Cash Flows | N.A | 76M | 18M |
| Cash Flow Financing | -2.05B | -0.99B | -1.05B |
| Exchange Rate Effect | N.A | 60M | -67M |
Bristol-Myers Squibb Company cash flow (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Net Income | -1.06B | 1.35B | 1.43B | 1.71B |
| Depreciation | 1.24B | 171M | 169M | 170M |
| Changes in Receivables | -2.19B | 214M | 142M | 421M |
| Changes in Inventories | 470M | -35M | -7M | 35M |
| Cash Change | -17.67B | 2.09B | 21.07B | 424M |
| Cash Flow | 2.04B | 2.56B | 2.08B | 1.39B |
| Capital Expenditures | -251M | -190M | -191M | -204M |
| Investments | -0.97B | -1.03B | 743M | 1.11B |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | -12.04B | 491M | 715M | 1.06B |
| Dividends Paid | -668M | -671M | -671M | -669M |
| Net Borrowings | 4M | 31M | 18.94B | -1.32B |
| Other Financing Cash Flows | -13M | -1M | -2M | -37M |
| Cash Flow Financing | -7.68B | -0.94B | 18.27B | -2.03B |
| Exchange Rate Effect | 6M | -21M | 3M | 3M |
Bristol-Myers Squibb Company cash flow (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Net Income | 1.19B | 1.90B | 373M | 1.49B |
| Depreciation | 172M | 165M | 157M | 143M |
| Changes in Receivables | -251M | -492M | 51M | 495M |
| Changes in Inventories | -64M | -30M | -118M | -4M |
| Cash Change | 1.50B | 409M | -343M | -79M |
| Cash Flow | 2.43B | 1.28B | 1.06B | 1.18B |
| Capital Expenditures | -290M | -224M | -198M | -239M |
| Investments | -317M | -242M | 476M | 157M |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | -336M | -147M | -348M | -43M |
| Dividends Paid | -653M | -653M | -654M | -653M |
| Net Borrowings | 74M | -71M | -207M | -344M |
| Other Financing Cash Flows | 1M | 4M | -1M | -58M |
| Cash Flow Financing | -578M | -720M | -1.02B | -1.22B |
| Exchange Rate Effect | -12M | -3M | -37M | 11M |
Bristol-Myers Squibb Company cash flow (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Net Income | -2.33B | 845M | 0.92B |
| Depreciation | 197M | 188M | 211M |
| Changes in Receivables | 341M | -115M | -115M |
| Changes in Inventories | -36M | 65M | 13M |
| Cash Change | 777M | 1.17B | -440M |
| Cash Flow | 1.12B | 1.71B | 1.58B |
| Capital Expenditures | -254M | -262M | -248M |
| Investments | 1.11B | 620M | -717M |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | 1.02B | 142M | -1.02B |
| Dividends Paid | -639M | -640M | -643M |
| Net Borrowings | -471M | 148M | -366M |
| Other Financing Cash Flows | 7M | 6M | 3M |
| Cash Flow Financing | -1.35B | -706M | -1.01B |
| Exchange Rate Effect | -7M | 25M | 6M |
Bristol-Myers Squibb Company dividends (USD)
| Ex date | Payment date | Record date | Declared date | Amount | Description | Frequency |
|---|---|---|---|---|---|---|
| 05-01-2023 | 01-02-2023 | 06-01-2023 | N.A | 0.57 | Ordinary Shares | Quarterly |
| 06-10-2022 | 01-11-2022 | 07-10-2022 | N.A | 0.54 | Ordinary Shares | Quarterly |
| 30-06-2022 | 01-08-2022 | 01-07-2022 | N.A | 0.54 | Ordinary Shares | Quarterly |
| 30-09-2021 | 01-11-2021 | 01-10-2021 | N.A | 0.49 | Ordinary Shares | Quarterly |
| 31-12-2020 | 01-02-2021 | 04-01-2021 | N.A | 0.49 | Ordinary Shares | Quarterly |
| 01-10-2020 | 02-11-2020 | 02-10-2020 | N.A | 0.45 | Ordinary Shares | Quarterly |
| 01-10-2020 | 02-11-2020 | 02-10-2020 | N.A | 0.45 | Ordinary Shares | Quarterly |
| 02-07-2020 | 03-08-2020 | 06-07-2020 | N.A | 0.45 | Ordinary Shares | Quarterly |
| 02-04-2020 | 01-05-2020 | 03-04-2020 | N.A | 0.45 | Ordinary Shares | Quarterly |
| 02-01-2020 | 03-02-2020 | 03-01-2020 | N.A | 0.45 | Ordinary Shares | Quarterly |
| 03-10-2019 | 01-11-2019 | 04-10-2019 | N.A | 0.41 | Ordinary Shares | Quarterly |
| 03-07-2019 | 01-08-2019 | 05-07-2019 | N.A | 0.41 | Ordinary Shares | Quarterly |
| 04-04-2019 | 01-05-2019 | 05-04-2019 | N.A | 0.41 | Ordinary Shares | Quarterly |
| 03-01-2019 | 01-02-2019 | 04-01-2019 | N.A | 0.41 | Ordinary Shares | Quarterly |
| 04-10-2018 | 01-11-2018 | 05-10-2018 | N.A | 0.40 | Ordinary Shares | Quarterly |
| 05-07-2018 | 01-08-2018 | 06-07-2018 | N.A | 0.40 | Ordinary Shares | Quarterly |
| 05-04-2018 | 01-05-2018 | 06-04-2018 | N.A | 0.40 | Ordinary Shares | Quarterly |
| 04-01-2018 | 01-02-2018 | 05-01-2018 | N.A | 0.40 | Ordinary Shares | Quarterly |
| 05-10-2017 | 01-11-2017 | 06-10-2017 | N.A | 0.39 | Ordinary Shares | Quarterly |
| 05-07-2017 | 01-08-2017 | 07-07-2017 | N.A | 0.39 | Ordinary Shares | Quarterly |
| 05-04-2017 | 01-05-2017 | 07-04-2017 | N.A | 0.39 | Ordinary Shares | Quarterly |
| 04-01-2017 | 01-02-2017 | 06-01-2017 | N.A | 0.39 | Ordinary Shares | Quarterly |
| 05-10-2016 | 01-11-2016 | 07-10-2016 | N.A | 0.38 | Ordinary Shares | Quarterly |
| 29-06-2016 | 01-08-2016 | 01-07-2016 | N.A | 0.38 | Ordinary Shares | Quarterly |
| 30-03-2016 | 02-05-2016 | 01-04-2016 | N.A | 0.38 | Ordinary Shares | Quarterly |
| 30-12-2015 | 01-02-2016 | 04-01-2016 | N.A | 0.38 | Ordinary Shares | Quarterly |
| 30-09-2015 | 02-11-2015 | 02-10-2015 | N.A | 0.37 | Ordinary Shares | Quarterly |
| 01-07-2015 | 03-08-2015 | 06-07-2015 | N.A | 0.37 | Ordinary Shares | Quarterly |
Total Valuation
Bristol-Myers Squibb Co. has a market cap or net worth of $142.35 billion. The enterprise value is $172.42 billion.
Market Cap
142.35B
Enterprise Value
172.42B
Important Dates
Earnings Date
Apr 27, 2023
Ex-Dividend Date
n.a
Share Statistics
Bristol-Myers Squibb Co. has 2.10 billion shares outstanding.
Shares Outstanding
2.10B
Float
n.a
Valuation Ratios
The trailing PE ratio is 22.4991 and the forward PE ratio is 8.3787. Bristol-Myers Squibb Co.'s PEG ratio is -4.1949.
PE Ratio
22.4991
Forward PE
8.3787
PS Ratio
3.0800
PB Ratio
4.5800
PEG Ratio
-4.1949
Stock Price Statistics
The stock price has decreased by -0.0519%. The beta is 0.2927, so Bristol-Myers Squibb Co.'s price volatility has been lower than the market average.
Beta (1Y)
0.2927
52-Week Price Change
-0.0519%
50-Day Moving Average
69.49
200-Day Moving Average
72.45
Average Volume (30 Days)
8.52M
Income Statement
In the last 12 months, Bristol-Myers Squibb Co. had revenue of $46.16 billion and earned $36.02 billion in profits. Earnings per share was $2.95.
Revenue
46.16B
Gross Profit
36.02B
EBITDA
18.70B
Earnings per Share
2.95
About
Ticker Symbol
BMY
Reporting Currency
USD
Key Executives
MCBRIDE ANTHONY A
SVP HR
JUDGE ANN POWELL
SVP, Global Human Resources
Caldarella Joseph C
VP & Financial Controller
Hirawat Samit
EVP,Chief Med.Offr.,Drug Dev.
Caforio Giovanni
Chief Operating Officer
Dubow Adam
SVP,ChiefCompliance&EthicsOff.
Biondi Paul
SVP, Head of Strategy & BD
Shanahan Karin
EVP, Glob. Prod. Dev. & Supply
Weese Michelle
EVP, Corporate Affairs
Bancroft Charles A
EVP, Head of Integration